In this issue:
Tisagenlecleucel in paediatric/young patients with R/R B-ALL
Second-line lisocabtagene maraleucel in primary refractory/early relapsed LBCL
Brentuximab vedotin + doxorubicin & dacarbazine in nonbulky stage I-II Hodgkin lymphoma
Curative vs. palliative treatment in patients >85 years with diffuse LBCL
Real-world survival of patients with mantle cell lymphoma
Nelarabine monotherapy vs. combination therapy for R/R T-ALL/LBL
Decitabine vs. hydroxyurea for advanced MP-CMML
DNA sequencing in AML prior to HSCT
Venetoclax + azacitidine vs. intensive chemotherapy for AML
Survival predictive factors in TP53-mutated AML with allo-HSCT
Please login below to download this issue (PDF)